Cancer-associated weight loss is linked to worse survival outcomes among patients with cancer.
While CDI is becoming more common in all hospitalized patients, patients with cancer appear to be at an elevated risk.
A list of drugs used for the treatment of nausea. The chart includes the formulations, strengths, and usual doses for each antiemetic drug product.
Previous studies demonstrated that inotuzumab ozogamicin significantly improves clinical outcomes vs standard of care chemotherapy, but impact on QoL was unknown.
A variety of cognitive impairments are common in the elderly US population, with as many as 14% of individuals over 70 being affected by dementia.
The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.
The impact of cancer-specific stress on psychological and physical functioning among patients with CLL was not previously well-understood.
Regular exercise can help patients with cancer deal with issues related to weight gain during treatment.
Two cases raise the question of whether abnormal activation of the hedgehog signaling pathway can lead to a protective effect on melanomas.
Previous epidemiological studies have indicated inconsistent results regarding the correlation between antidepressant use and ovarian cancer risk.
Short-term incidence of leukemia, lymphoma, and brain cancer may be higher in children who were hospitalized with pneumonia.
Previous studies showed that there may be an association between ITP and CVD — especially among those who undergo splenectomy — but evidence is conflicting.
Among patients with cancer, those with head and neck cancer have among the highest rates of depression.
As failure to recognize depression symptoms contributes to the association between mortality and depression in cancer patients, early recognition and treatment with pharmacologic and/or psychologic support is essential for improving outcomes.
Management of malignant pleural effusions should be tailored to the particular patient, depending on preference, prognosis, and variety of underlying disease.
Access to treatment should be considered as important as the research leading to clinical improvements.
While some researchers are attempting to determine whether cannabis has any anti-tumor activity, the FDA recommends that patients do not listen to websites touting the benefits of cannabidiol.
The drug addiction strategy must be broadened to account for non-addicted cells, sensitive or resistant, that remain after therapy. Much as selection should favor the development of drug resistant tumor cell lineages, it should also favor lineages that are resistant to addiction.
The rate of confirmed seizures compared favorably with a retrospective study that noted a seizure rate of 2.8 per 100 patient-years among patients with mCRPC and risk factors for seizure who did not receive enzalutamide.
The results of this study support previous findings that psychological distress is associated with an increased risk of mortality among patients with lung cancer.
Researchers injected Ewing sarcoma cells into mice to determine the effects of exercise on doxorubicin efficacy and treatment-related cardiotoxicity.
Researchers at the Seattle Cancer Care Alliance used email and web screening to determine patient quality of life and psychological comorbidities after a sarcoma diagnosis.
Researchers enrolled survivors of breast cancer, colorectal cancer, or melanoma to participate in ConquerFear or a control intervention, Taking-it-Easy, and to complete accompanying questionnaires.
Patients with underlying cardiovascular disease and/or baseline hypertension and coronary artery disease may be at a higher risk.
Previous studies show that eltrombopag treatment for 6 months or less effectively increases platelet counts and reduces bleeding among patients with chronic ITP.
The modern opioid epidemic is forcing health care providers and government agencies to reevaluate pain management, but there is a lack of data regarding the risk of opioid-misuse among vulnerable populations.
Researchers analyzed the outcomes of 7060 patients with SCLC from the SEER database to determine the rates of new CEs among patients treated with chemotherapy plus RT or chemotherapy alone.
During the pre-chemotherapy period, which lasted a median 48 days from diagnosis, the average cost per payment was $16,208, 41% of which was due to inpatient care.
Pain management continues to be a challenge for patients with pancreatic cancer, though CPN may provide significant pain relief and an opportunity to reduce the amount of required narcotics.
Researchers evaluated data from 14,715 men with PCa from the Taiwan National Health Insurance Research Database, of whom 24.3% underwent bilateral orchiectomies and 75.7% received GnRHa therapy.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy